Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by educational grants from Sanofi Genzyme.
Oncology Briefings™: Coordinating the Long-Term Management of Patients with Multiple Myeloma Between Primary Care and Oncology Practice
Release Date: September 15, 2021
Expiration Date: September 15, 2022
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate.
This educational activity is directed toward medical oncologists and primary care physicians who treat or manage patients with multiple myeloma. Nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals interested in the treatment of myeloma are invited to participate.
Upon successful completion of this activity, you should be better prepared to:
- Determine the impact of comorbidities, risk stratification, and treatment history on therapy selection in MM across therapy lines
- Evaluate the clinical profiles of current and emerging therapies for patients with newly diagnosed and relapsed/refractory MM
- Implement proactive strategies to identify and manage treatment-related toxicities in patents with MM
- Apply updated clinical data and guidelines to real-world clinical scenarios of patients with MM across treatment settings, with a focus on multidisciplinary coordination and management of comorbidities and treatment-related toxicities
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
Professor and Chair,
Department of Hematology and Medical Oncology
Anne and Bernard Gray Professor in Cancer,
Emory University School of Medicine
Chief Medical Officer,
Winship Cancer Institute of Emory University
Disclosures: Grant Research Support: BMS, Celgene, Janssen, Takeda; Consultant: AbbVie, Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen Sanofi, Juno Therapeutics, Novartis, Takeda; Other: TG Therapeutics (Board of Directors).
Assistant Professor of Internal Medicine
Emory University School of Medicine
Disclosures: Dr. Jennifer Zreloff, MD has no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.